Medicine:ReCOV
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
ReCOV is a COVID-19 vaccine candidate developed by Jiangsu Rec-Biotechnology Co Ltd.[1][2][3][4]
References
- ↑ Clinical trial number NCT04818801 for "Safety, Reactogenicity and Immunogenicity Study of ReCOV" at ClinicalTrials.gov
- ↑ Clinical trial number NCT05084989 for "Efficacy, Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)" at ClinicalTrials.gov
- ↑ "New Covid-19 vaccine developed in China is being tested on Kiwis". Stuff. 24 June 2021. https://www.stuff.co.nz/national/health/coronavirus/125540743/new-covid19-vaccine-developed-in-china-is-being-tested-on-kiwis.
- ↑ "Coronavirus: China-made 'ReCov' vaccine may be better than Pfizer-BioNTech's, New Zealand doctor says; Sydney faces 'scariest period' of pandemic". South China Morning Post. 24 June 2021. https://www.scmp.com/news/asia/article/3138535/coronavirus-china-made-recov-vaccine-may-be-better-pfizer-biontechs-new.
 |
